CRIS Current Research Information System

ZINZANI, PIER LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 34.493
NA - Nord America 34.049
EU - Europa 22.942
SA - Sud America 2.463
Continente sconosciuto - Info sul continente non disponibili 1.884
AF - Africa 1.414
OC - Oceania 76
Totale 97.321
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 33.308
SG - Singapore 9.200
CN - Cina 9.041
VN - Vietnam 8.099
GB - Regno Unito 4.525
IT - Italia 4.218
DE - Germania 2.977
NL - Olanda 2.599
HK - Hong Kong 2.301
SE - Svezia 2.259
BR - Brasile 1.791
FR - Francia 1.519
IN - India 1.451
KR - Corea 1.197
RU - Federazione Russa 1.182
BD - Bangladesh 1.043
UA - Ucraina 813
IE - Irlanda 692
JP - Giappone 642
FI - Finlandia 608
ZA - Sudafrica 468
CA - Canada 347
CI - Costa d'Avorio 316
EE - Estonia 309
AR - Argentina 279
ID - Indonesia 217
TG - Togo 203
CH - Svizzera 197
PH - Filippine 174
AT - Austria 164
MX - Messico 163
PL - Polonia 151
JO - Giordania 147
TH - Thailandia 139
HR - Croazia 133
SC - Seychelles 125
IQ - Iraq 114
ES - Italia 109
TR - Turchia 105
EC - Ecuador 101
BG - Bulgaria 93
TW - Taiwan 90
BE - Belgio 89
NG - Nigeria 83
PK - Pakistan 76
SA - Arabia Saudita 73
CL - Cile 68
CO - Colombia 62
AU - Australia 61
IR - Iran 58
GR - Grecia 55
VE - Venezuela 51
JM - Giamaica 47
UZ - Uzbekistan 47
EG - Egitto 45
PY - Paraguay 44
MY - Malesia 39
CR - Costa Rica 37
LB - Libano 36
MA - Marocco 32
RO - Romania 32
LT - Lituania 31
PE - Perù 31
IL - Israele 28
DZ - Algeria 25
CZ - Repubblica Ceca 24
AE - Emirati Arabi Uniti 23
AL - Albania 23
TN - Tunisia 23
KE - Kenya 22
LU - Lussemburgo 21
PT - Portogallo 21
DO - Repubblica Dominicana 20
AZ - Azerbaigian 19
KZ - Kazakistan 19
EU - Europa 18
GT - Guatemala 18
BO - Bolivia 17
RS - Serbia 17
NP - Nepal 16
OM - Oman 16
UY - Uruguay 16
ET - Etiopia 15
PR - Porto Rico 15
TT - Trinidad e Tobago 15
HN - Honduras 14
DK - Danimarca 13
NI - Nicaragua 13
HU - Ungheria 12
NZ - Nuova Zelanda 11
BY - Bielorussia 10
PA - Panama 10
SV - El Salvador 10
GH - Ghana 8
GE - Georgia 7
KG - Kirghizistan 7
LY - Libia 7
MD - Moldavia 7
SK - Slovacchia (Repubblica Slovacca) 7
SN - Senegal 7
Totale 95.280
Salva come PNG Salva come JPEG
Città #
Singapore 6.366
Southend 3.817
Ashburn 3.285
Fairfield 3.122
Hefei 2.545
San Jose 2.203
Hong Kong 2.172
Ho Chi Minh City 1.885
Chandler 1.649
Hanoi 1.532
Woodbridge 1.507
Houston 1.502
Seattle 1.401
Wilmington 1.375
Eygelshoven 1.296
Santa Clara 1.179
Cambridge 1.111
Princeton 1.091
Seoul 1.087
Ann Arbor 1.038
Beijing 862
Boardman 837
Dong Ket 762
Lauterbourg 728
Dublin 692
Kerkrade 666
Bologna 663
Los Angeles 608
New York 585
Tokyo 546
Frankfurt am Main 543
Council Bluffs 513
Helsinki 465
Milan 443
Jacksonville 427
Nanjing 422
Westminster 412
Dallas 373
Buffalo 351
Berlin 342
Padova 337
Abidjan 316
Da Nang 269
Haiphong 247
Jinan 236
Bengaluru 234
São Paulo 223
Rome 215
Redondo Beach 212
Chicago 208
Lomé 202
San Diego 202
Shenyang 195
Saint Petersburg 192
Changsha 174
Guangzhou 162
Turin 159
Nuremberg 148
Shanghai 148
Amman 145
Hebei 134
London 131
Nanchang 131
Tianjin 131
Bern 127
Jakarta 124
Zhengzhou 120
Bremen 119
Munich 119
Bar Harbor 111
Lappeenranta 111
Phoenix 107
Hangzhou 100
Toronto 98
Warsaw 98
Des Moines 96
Mülheim 94
Florence 93
Redmond 93
Redwood City 93
Jiaxing 90
The Dalles 90
Biên Hòa 89
Amsterdam 86
Johannesburg 85
Sofia 84
Hyderabad 82
Hải Dương 82
Falls Church 80
Brooklyn 78
Olalla 78
Dearborn 76
Vienna 75
Yubileyny 75
San Francisco 73
Atlanta 72
Falkenstein 72
Brussels 71
Orem 71
Norwalk 70
Totale 60.436
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 2.865
Consensus conference on the management of tumor lysis syndrome. 480
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 459
Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. 365
CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells 341
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 325
18F-FDG PET early after radiotherapy in lymphoma patients. 321
Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets 305
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 294
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens 287
Biology and treatment of follicular lymphoma. 285
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium 280
Gastric MALT Lymphoma in a Sleeve Gastrectomy Specimen: Case Report and Literature Review 280
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. 272
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 267
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 261
A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine 258
Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma – Authors' reply 258
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 258
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome 258
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 256
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 253
CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. 252
Intracranial pressure management in fulminant cerebral oedema after CAR T-cell therapy: Not all is lost! 248
18 F-FDG PET in malignant lymphoma: significance of positive findings 247
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 247
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 244
Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling 244
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 244
Peripheral blood cellular profile at pre-lymphodepletion is associated with {CD}19-targeted {CAR}-T cell-associated neurotoxicity 241
Detection of Brain-Derived Cell-Free DNA in Plasma 240
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 239
T-Cell Lymphomas in South America and Europe 234
Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. 233
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 232
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 232
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 230
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 230
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 227
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 227
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 226
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma 225
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 224
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 224
Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy 223
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 223
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report 223
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. 222
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 221
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. 220
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program 220
An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature. 219
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 217
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 217
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 215
The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients 213
CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON–NEUTRAL): proposed protocol and results from an Italian study 212
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 212
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 212
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 212
Expression of CD52 in peripheral T-cell lymphoma. 211
RALE051: a novel established cell line of sporadic Burkitt lymphoma 210
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 210
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 209
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 207
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 207
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 205
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 204
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma 204
Lymphoma: diagnosis, staging, natural history, and treatment strategies. 203
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 203
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 202
Primary non-hodgkin’s lymphoma of bone: treatment and analysis of prognostic factors for stage I and stage II 202
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 201
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 200
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial 199
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. 198
Enteropathy-associated T-cell lymphoma. 197
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study 196
Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. 195
The role of mitoxantrone in the treatment of indolent lymphomas. 195
Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-D-glucose uptake in heavily pre-treated lymphoma patients 195
CD30 expression in peripheral T-cell lymphomas 195
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 195
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 195
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial 195
Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome 194
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma 193
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 193
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 193
Genetics and clinical phenotype of Erdheim–Chester disease: A case report of constrictive pericarditis and a systematic review of the literature 192
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study 191
Histopathology of B-cell chronic lymphocytic leukemia. 191
Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients. 191
Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway. 191
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 190
Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. 188
Autologous hematopoietic stem cell transplantation in Non-Hodgkin's lymphomas. 188
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. 188
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. 188
Totale 25.803
Salva come PNG Salva come JPEG
Categoria #
all - tutte 271.364
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 271.364
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20227.368 0 251 567 737 812 444 178 671 307 477 1.593 1.331
2022/20238.447 973 1.102 503 1.028 698 601 280 540 1.390 301 606 425
2023/20242.799 180 449 201 270 223 374 177 180 98 278 218 151
2024/202514.004 430 2.120 1.121 963 1.794 681 1.165 392 347 1.025 1.003 2.963
2025/202639.515 3.055 4.480 3.615 2.872 3.298 3.296 4.539 1.990 5.850 2.616 2.049 1.855
2026/20272.325 1.477 848 0 0 0 0 0 0 0 0 0 0
Totale 97.321